In Wednesday’s Wall Street session, Capricor Therapeutics Inc (NASDAQ:CAPR) shares traded at $6.89, down -5.62% from the previous session.
CAPR stock price is now -41.30% away from the 50-day moving average and -44.45% away from the 200-day moving average. The market capitalization of the company currently stands at $314.71M.
With the price target of $35, Piper Sandler recently initiated with Overweight rating for Capricor Therapeutics Inc (NASDAQ: CAPR). On May 17, 2024, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $14, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Nippon Shinyaku Co Ltd, 10% Owner bought 2,798,507 shares of the company’s stock on Sep 20 ’24. The stock was bought for $14,999,998 at an average price of $5.36. Upon completion of the transaction, the 10% Owner now directly owns 7,090,351 shares in the company, valued at $48.85 million. A total of 12.16% of the company’s stock is owned by insiders.
During the past 12 months, Capricor Therapeutics Inc has had a low of $3.52 and a high of $23.40. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 7.77, and a quick ratio of 7.77.
The net profit margin was -181.71% and return on equity was -48.16% for CAPR. The company reported revenue of $11.13 million for the quarter, compared to $12.09 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -7.92 percent.
